US 7,468,355 B2
Methods for inhibiting cancer and scar formation
Hamdi K. Hamdi, Los Angeles, Calif. (US); and Raquel Castellon, Norwalk, Calif. (US)
Assigned to H2RC Corporation, Los Angeles, Calif. (US)
Filed on Nov. 13, 2003, as Appl. No. 10/712,423.
Application 10/712423 is a continuation in part of application No. 10/657414, filed on Sep. 08, 2003, abandoned.
Application 10/657414 is a continuation of application No. 10/153003, filed on May 22, 2002, granted, now 6,632,798.
Claims priority of provisional application 60/431780, filed on Dec. 09, 2002.
Prior Publication US 2004/0097428 A1, May 20, 2004
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/70 (2006.01); A61K 31/35 (2006.01)
U.S. Cl. 514—27  [514/460] 20 Claims
 
1. A method for treating cancer in a subject, wherein the cancer is selected from the group consisting of colon cancer, renal adenocarcinoma, and melanoma;
the method comprising administering to a subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition having chemopreventive activity which contains as an active ingredient a therapeutically effective quantity of a compound of the formula or its enantiomer:

OG Complex Work Unit Drawing
wherein R1 and R2 are functional groups selected from the group of hydroxyl, —NH2, —SH;
R3 is a functional group selected from the group consisting of hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, hydroxyl, C1-C6-alkoxy, halogen, NO2, NH3 and COOCH3;
X1-X3 are functional groups selected from the group consisting of oxygen, sulfur, —CH2—, or carboxy;
R4 is a functional group selected from the group consisting of hydrogen, C1-C6-alkoxy, glucose, B-D-glucopyranose, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, hydroxyl, halogen NO2, NH3, carbohydrate, amino acid, nucleotide and lipid; and
R5 is a functional group selected from the group consisting of hydrogen, C1-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, aryl, hydroxyl, C1-C6-alkoxy, halogen, NO2, NH3, and CH3.